Company Profile
Verrica Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- VRCA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.89 USD (-1.61%)
Close
Last updated: August 17, 2026
99.5M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, VRCA closed down 1.61% at $4.89. No new same-company headline was identified in the current news window.
Company overview
Medical Dermatology
Verrica Pharmaceuticals develops and commercializes treatments for dermatologic diseases, including viral skin conditions and non-melanoma skin cancers.
YCANTH for Molluscum
YCANTH is a drug-device combination containing a controlled formulation of cantharidin in a single-use applicator. It is the first FDA-approved, healthcare-professional-administered treatment for molluscum contagiosum in adults and children two years of age and older.
Common-Wart Expansion
Verrica is evaluating YCANTH in the global pivotal COVE-2 and COVE-3 Phase 3 studies for common warts. The program is intended to extend the product into a substantially larger dermatology population.
VP-315 Skin-Cancer Program
VP-315, or ruxotemitide, is a licensed oncolytic peptide being prepared for Phase 3 development in basal cell carcinoma. The broader license also covers other non-melanoma skin cancers, including squamous cell carcinoma.
Future catalysts
- Topline results from the global Phase 3 YCANTH program in common warts in mid-2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Verrica Pharmaceuticals (VRCA)?
Verrica Pharmaceuticals (VRCA) most recently closed at 4.89 USD, a -1.61% move versus the previous session.
What is the market cap of Verrica Pharmaceuticals (VRCA)?
Verrica Pharmaceuticals currently has a market capitalization of 99.5M USD on BioPharmSignal.
What does Verrica Pharmaceuticals do?
Medical Dermatology Verrica Pharmaceuticals develops and commercializes treatments for dermatologic diseases, including viral skin conditions and non-melanoma skin cancers. YCANTH for Molluscum YCANTH is a drug-device combination containing a controlled formulation of cantharidin in a single-use applicator. It is the first FDA-approved,...
On which exchange is VRCA stock listed?
Verrica Pharmaceuticals (VRCA) is associated with NASDAQ, United States, Biopharma.
What is COVE-2?
Common-Wart Expansion Verrica is evaluating YCANTH in the global pivotal COVE-2 and COVE-3 Phase 3 studies for common warts.
Which conditions is Verrica Pharmaceuticals targeting with COVE-2?
Verrica Pharmaceuticals is associated with cancer therapeutics, dermatology based on its company overview and current catalyst commentary.
How does Verrica Pharmaceuticals describe recent progress with COVE-2?
Topline results from the global Phase 3 YCANTH program in common warts in mid-2027.
What is COVE-3?
Common-Wart Expansion Verrica is evaluating YCANTH in the global pivotal COVE-2 and COVE-3 Phase 3 studies for common warts.